NYSE · Health care

GSK plc (GSK)

GSK plc reported revenue of £32.7B in fiscal 2025, up 4.1% from a year earlier. Net income was £5.7B, a net margin of 17.5%. Operating cash flow minus capital spending left £6.4B of free cash flow in fiscal 2025. At December 31, 2025 it held £3.4B in cash against £14.5B of debt.

Watch GSK in 60 seconds

Price

$49.70

+0.93% on the day · September 28, 2026

52-week range $40.36 to $61.70

Market cap

$100.6B

Revenue (FY2025)

£32.7B

+4.1% year on year

Net margin

17.5%

What GSK plc does

GSK is a biopharmaceutical company that researches, develops, and manufactures prescription medicines and vaccines. Its product portfolio focuses on infectious diseases, human immunodeficiency virus (HIV) treatments, immunology, and oncology. Its medicines and vaccines are sold to healthcare systems, hospitals, pharmacies, and governments globally. Its shares trade on NYSE under the ticker GSK.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in GBP.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	£32.7B	£7.9B	£5.7B	£1.39	£6.4B
2024	£31.4B	£4B	£2.6B	£0.62	£5.2B
2023	£30.3B	£6.7B	£4.9B	£1.20	£5.5B
2022	£29.3B	£6.4B	£15B	£3.66	£6.3B
2021	£24.7B	£4.4B	£4.4B	£1.08	£7B
2020	£24.4B	£6B	£5.7B	£1.43	£7.5B

Full financial statements: income, balance sheet and cash flow

Where GSK ranks in Health care

Revenue growth+4.1%

#363 of 529 in Health care · Bottom 31%

Net margin17.5%

#70 of 541 in Health care · Top 13%

Free cash flow margin19.6%

#60 of 488 in Health care · Top 12%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Dividends

It paid out £2.6B in cash dividends, 45% of its net income.

Fiscal year	Per share	Paid out	Of profit
2025	n/a	£2.6B	45%
2024	n/a	£2.4B	95%
2023	n/a	£2.2B	46%
2022	n/a	£3.5B	23%
2021	n/a	£4B	91%
2020	n/a	£4B	69%

Per share as declared (or paid, where only that is reported), adjusted for stock splits the company itself restated. Yield is the latest fiscal year's dividend over the current price.

Latest SEC filings

What GSK plc has filed recently, newest first. Each links to the original document on SEC EDGAR.

September 24, 2026
Foreign issuer update 6-K
September 22, 2026
Foreign issuer update 6-K
September 15, 2026
Foreign issuer update 6-K
September 15, 2026
Foreign issuer update 6-K
September 14, 2026
Foreign issuer update 6-K
September 14, 2026
Foreign issuer update 6-K
September 11, 2026
Foreign issuer update 6-K
September 10, 2026
Foreign issuer update 6-K
September 10, 2026
Securities offering prospectus 424B2
September 10, 2026
Foreign issuer update 6-K

Recent insider filings (Forms 3, 4 and 144): 8, the latest on August 20, 2026. Insider transactions on SEC

Insider trades

What the people running GSK plc did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

Bought (open market)

last 90 days

Sold

last 90 days

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns GSK

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Holder	Of class	Shares	Filed
Fmr LLC13G, passive with 1 related filers	5.8%	234,936,061	May 6, 2026

Latest filings below 5%: Dodge & Cox 4.3% (August 13, 2026).

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

No insider reported holdings on a Form 4 in the last 12 months.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about GSK

What does GSK plc do?

Is GSK plc profitable?

Yes. In fiscal 2025 it reported net income of £5.7B on revenue of £32.7B, a net margin of 17.5%.

How much revenue does GSK plc make?

In fiscal 2025 GSK plc reported revenue of £32.7B. That is 4.1% more than a year earlier.

When did GSK plc last report?

Its newest filing of any kind is the foreign issuer update from September 24, 2026.

Similar companies

TAK

Takeda Pharmaceutical Co Ltd

Compare GSK with

Compare GSK with any company

Follow GSK

Get an email when GSK plc files with the SEC: results, executive changes, material agreements and annual reports.

Follow GSK: get an email when it files

Where the numbers come from

Financial figures are the values GSK plc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.